Toggle Main Menu Toggle Search

Open Access padlockePrints

Impaired functional vitamin B6 status is associated with increased risk of lung cancer

Lookup NU author(s): Professor Caroline Relton, Dr Paul Brennan

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2017 UICC Circulating vitamin B6 levels have been found to be inversely associated with lung cancer. Most studies have focused on the B6 form pyridoxal 5′-phosphate (PLP), a direct biomarker influenced by inflammation and other factors. Using a functional B6 marker allows further investigation of the potential role of vitamin B6 status in the pathogenesis of lung cancer. We prospectively evaluated the association of the functional marker of vitamin B6 status, the 3-hydroxykynurenine:xanthurenic acid (HK:XA) ratio, with risk of lung cancer in a nested case–control study consisting of 5,364 matched case–control pairs from the Lung Cancer Cohort Consortium (LC3). We used conditional logistic regression to evaluate the association between HK:XA and lung cancer, and random effect models to combine results from different cohorts and regions. High levels of HK:XA, indicating impaired functional B6 status, were associated with an increased risk of lung cancer, the odds ratio comparing the fourth and the first quartiles (OR4th vs. 1st) was 1.25 (95% confidence interval, 1.10–1.41). Stratified analyses indicated that this association was primarily driven by cases diagnosed with squamous cell carcinoma. Notably, the risk associated with HK:XA was approximately 50% higher in groups with a high relative frequency of squamous cell carcinoma, i.e., men, former and current smokers. This risk of squamous cell carcinoma was present in both men and women regardless of smoking status.


Publication metadata

Author(s): Theofylaktopoulou D, Midttun O, Ueland PM, Meyer K, Fanidi A, Zheng W, Shu X-O, Xiang Y-B, Prentice R, Pettinger M, Thomson CA, Giles GG, Hodge A, Cai Q, Blot WJ, Wu J, Johansson M, Hultdin J, Grankvist K, Stevens VL, McCullough MM, Weinstein SJ, Albanes D, Ziegler R, Freedman ND, Langhammer A, Hveem K, Naess M, Sesso HD, Gaziano JM, Buring JE, Lee I-M, Severi G, Zhang X, Stampfer MJ, Han J, Smith-Warner SA, Zeleniuch-Jacquotte A, Le Marchand L, Yuan J-M, Wang R, Butler LM, Koh W-P, Gao Y-T, Rothman N, Ericson U, Sonestedt E, Visvanathan K, Jones MR, Relton C, Brennan P, Johansson M, Ulvik A

Publication type: Article

Publication status: Published

Journal: International Journal of Cancer

Year: 2018

Volume: 142

Issue: 12

Pages: 2425-2434

Print publication date: 15/06/2018

Online publication date: 14/12/2017

Acceptance date: 22/11/2017

ISSN (print): 0020-7136

ISSN (electronic): 1097-0215

Publisher: Wiley-Liss Inc.

URL: https://doi.org/10.1002/ijc.31215

DOI: 10.1002/ijc.31215


Altmetrics

Altmetrics provided by Altmetric


Share